MT1980 / Monument Therap, TRx Biosci - LARVOL DELTA

TARGETING NEUROINFLAMMATION IN NEURODEGENERATIVE DISORDERS: A FIRST IN HUMAN STUDY OF MT1980, A NOVEL FORMULATED ANTI-INFLAMMATORY MEDICINE (ADPD 2023) - "Concentrations of drug achieved in the CSF were at levels anticipated to provide meaningful anti-inflammatory effects, suggesting MT1980 has potential utility as a novel treatment of neuroinflammatory conditions. A further clinical study to assess PK and anti-neuroinflammatory effects is now planned."

P1 data • Alzheimer's Disease • CNS Disorders • Immunology • Inflammation

Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Monument Therapeutics Limited | Active, not recruiting ➔ Completed

Trial completion • Inflammation

Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Monument Therapeutics Limited | Recruiting ➔ Active, not recruiting

Enrollment closed • Inflammation

Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Monument Therapeutics Limited

New P1 trial • Inflammation